What is claimed is:

1. A method of treating psoriatic arthritis comprising administering to a patient having psoriatic arthritis a therapeutically effective amount of TNFR:Fc.

2. The method of Claim 1, wherein the TNFR:Fc is administered in an amount and for a time sufficient to induce an improvement over baseline in an indicator selected from the group consisting of: 1) joint swelling; 2) joint pain or tenderness; 3) patient self-assessment; 4) physician assessment;5) psoriasis area and severity index (PASI); and 6) psoriasis Target Lesion Assessment score.

3. The method of Claim 1, wherein the TNFR:Fc is administered one or more times per week.

4. The method of Claim 3, wherein the TNFR:Fc is administered two times per week.

5. The method of Claim 1, wherein the TNFR:Fc is administered by injection.

6. The method of Claim 5, wherein the amount of TNFR:Fc injected is 5-12 mg/m^2 or 25 mg.

7. The method of Claim 1, wherein the TNFR:Fc is administered concurrently with one or more medications selected from the group consisting of disease-modifying anti-rheumatic drugs; non-steroidal anti-inflammatory drugs; pain medications; corticosteroids; retinoids; antagonists of inflammatory cytokines; and antibodies against T cell surface proteins.

8. The method of Claim 7, wherein the concurrently administered medication is methotrexate or sulfasalazine.

9. The method of Claim 1, wherein the TNFR:Fc is administered concurrently with an antagonist of Il-1, Il-6 or Il-8.

10. The method of Claim 1, wherein the TNFR:Fc is administered concurrently with one or more disease-modifying anti-rheumatic drug and one or more non-steroidal anti-inflammatory drug.

11. The method of Claim 1, wherein the TNFR:Fc is administered in a sustained-release form selected from the group consisting of TNFR:Fc that is encapsulated in a biocompatible polymer; TNFR:Fc that is admixed with a biocompatible polymer; and TNFR:Fc that is encased in a semi-permeable implant.

12. A method of treating psoriatic arthritis in a patient who is between the ages of 4 and 17 comprising administering to said patient a therapeutically effective amount of TNFR:Fc, wherein the TNFR:Fc is administered in a dose of 0.4 mg/kg, up to a maximum of 25 mg, of TNFR:Fc two times per week or three times per week.

13. A method of treating a patient having psoriatic arthritis comprising administering to said patient a dose of 25 mg of TNFR:Fc that is injected two times per week for one week or longer.

14. A method of treating psoriasis comprising administering to a patient having psoriasis a therapeutically effective amount of a TNFα antagonist comprising a soluble recombinant TNFα receptor.

15. The method of Claim 14, wherein the soluble TNFα receptor is administered in an amount and for a time sufficient to induce an improvement over baseline in an indicator selected from the group consisting of psoriasis area and severity index (PASI) and Target Lesion Assessment Score.

16. The method of Claim 14, wherein the TNFα antagonist is TNFR:Fc.

17. The method of Claim 14, wherein the TNFR:Fc is administered by injection.

18. The method of Claim 17, wherein the amount of TNFR:Fc per dose is 5-12 mg/m^2 or 25 mg.

19. The method of Claim 17, wherein 20-25 mg of TNFR:Fc is injected at least one time per week.

20. The method of Claim 16, wherein the TNFR:Fc is administered concurrently with a treatment selected from the group consisting of: topical steroids; systemic steroids; anthralin; coal tar; vitamin D3 and its analogs; topical retinoids; salicylic acid; phototherapy with ultraviolet light B; psoralen combined with ultraviolet light A; non-steroidal anti-inflammatory drugs; methotrexate; oral retinoids; cyclosporine; hydroxyurea; and sulfasalazine.

21. A method of treating a patient having psoriasis who is between the ages of 4 and 17 comprising administering to said patient a therapeutically effective amount of TNFR:Fc, wherein the TNFR:Fc is administered in a dose of 0.4 mg/kg, up to a maximum of 25 mg, two times per week or three times per week.

22. A method of treating a patient having psoriasis comprising injecting said patient with 25 mg of TNFR:Fc two times per week for 2 or more weeks.